A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Renal Cell Carcinoma (RCC)
In brief
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Key facts
- Study ID
- NCT07293351
- Run by
- Bristol-Myers Squibb
- People needed
- 254
- Starts
- 2026-03-26
- Expected to finish
- 2031-11-26
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have a histologically confirmed diagnosis of locally advanced, unresectable (not amenable to curative surgery or radiation therapy) or metastatic Renal Cell Carcinoma (RCC).
- Participants must have clear cell RCC (ccRCC) or non-clear cell RCC (nccRCC) may be enrolled in Part 1. Note: Part 2 may only enroll participants with ccRCC.
- Participants may have favorable, intermediate or poor risk disease categories.
- Participants must not have received prior systemic therapy for metastatic RCC, with the following exceptions:
- i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC is allowed if such therapy did not include an agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
- ii) For Part 1A participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received any therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) (e.g., ipilimumab).
- iii) For Part 1B participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received prior treatment with cabozantinib.
- Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
You may not qualify if…
- Participants must not have any untreated known CNS metastases.
- Participants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of Cycle 1 Day1 (C1D1).
- Participants must not have a history of interstitial lung disease or pneumonitis.
- Participants must not have an uncontrolled pleural or pericardial effusion requiring recurrent therapeutic drainage procedures.
- Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to C1D1, uncontrolled hypertension (≥ 150 systolic, ≥ 90 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
- Participants must not have a urine protein ≥ 2+ and 24 hour urine protein ≥ 1 g at baseline.
- Participants must not have evidence of major coagulation disorders.
- Participants must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 6 months prior to C1D1.
- Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months.
- Participants must not have had a major surgery or trauma within 28 days prior to C1D1.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where it is running
- St Bartholomew's Hospital — London, London, City of, United Kingdom (enrolling)
- Memorial Sloan Kettering Cancer Center — Hauppauge, New York, United States (enrolling)
- Kyushu University Hospital — Fukuoka, Japan (enrolling)
- Royal Marsden Hospital (Chelsea) — London, Kensington and Chelsea, United Kingdom (enrolling)
- Royal Marsden Hospital Sutton — Sulton, Surrey, United Kingdom (enrolling)
- Velindre Cancer Centre — Cardiff, United Kingdom (enrolling)
- Bradfordhill — Santiago, Santiago Metropolitan, Chile (enrolling)
- The Cancer Institute Hospital of JFCR — Koto-ku, Tokyo, Japan (enrolling)
- HOCH Health Ostschweiz — Sankt Gallen, Switzerland (enrolling)
- UniversitätsSpital Zürich — Zurich, Switzerland (enrolling)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (enrolling)
- Sibley Memorial Hospital — Washington D.C., District of Columbia, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- MUSC Hollings Cancer Center — Charleston, South Carolina, United States (enrolling)
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina, United States (enrolling)
- Hospital Sirio Libanes — Brasília, Federal District, Brazil (enrolling)
- Johns Hopkins Hospital — Baltimore, Maryland, United States (enrolling)
- Instituto Medico Especializado Alexander Fleming — Buenos Aires, Argentina (enrolling)
- Kantonsspital Graubünden — Chur, Switzerland (enrolling)
- Macquarie University — North Ryde, New South Wales, Australia (enrolling)
- GenesisCare St Leonards — St Leonards, New South Wales, Australia (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Local Institution - 0170 — Fort Wayne, Indiana, United States
- Local Institution - 0003 — Malvern, Australia
- Local Institution - 0074 — South Brisbane, Queensland, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.